Are Markers of Inflammation More Strongly Associated with Risk for Fatal Than for Nonfatal Vascular Events?
Open Access
- 23 June 2009
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 6 (6) , e1000099
- https://doi.org/10.1371/journal.pmed.1000099
Abstract
Circulating inflammatory markers may more strongly relate to risk of fatal versus nonfatal cardiovascular disease (CVD) events, but robust prospective evidence is lacking. We tested whether interleukin (IL)-6, C-reactive protein (CRP), and fibrinogen more strongly associate with fatal compared to nonfatal myocardial infarction (MI) and stroke. In the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER), baseline inflammatory markers in up to 5,680 men and women aged 70–82 y were related to risk for endpoints; nonfatal CVD (i.e., nonfatal MI and nonfatal stroke [n = 672]), fatal CVD (n = 190), death from other CV causes (n = 38), and non-CVD mortality (n = 300), over 3.2-y follow-up. Elevations in baseline IL-6 levels were significantly (p = 0.0009; competing risks model analysis) more strongly associated with fatal CVD (hazard ratio [HR] for 1 log unit increase in IL-6 1.75, 95% confidence interval [CI] 1.44–2.12) than with risk of nonfatal CVD (1.17, 95% CI 1.04–1.31), in analyses adjusted for treatment allocation. The findings were consistent in a fully adjusted model. These broad trends were similar for CRP and, to a lesser extent, for fibrinogen. The results were also similar in placebo and statin recipients (i.e., no interaction). The C-statistic for fatal CVD using traditional risk factors was significantly (+0.017; pp = 0.20). In PROSPER, inflammatory markers, in particular IL-6 and CRP, are more strongly associated with risk of fatal vascular events than nonfatal vascular events. These novel observations may have important implications for better understanding aetiology of CVD mortality, and have potential clinical relevance. Please see later in the article for Editors' SummaryKeywords
This publication has 46 references indexed in Scilit:
- Leptin Predicts Diabetes but Not Cardiovascular DiseaseDiabetes Care, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic ReviewPLoS Medicine, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- C-Reactive Protein and All-Cause Mortality in a Large Hospital-Based CohortClinical Chemistry, 2008
- The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseasesEuropean Journal of Epidemiology, 2007
- Combinations of biomarkers predictive of later life mortalityProceedings of the National Academy of Sciences, 2006
- An Assessment of Incremental Coronary Risk Prediction Using C-Reactive Protein and Other Novel Risk MarkersArchives of internal medicine (1960), 2006
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- The design of a prospective study of pravastatin in the elderly at risk (PROSPER)The American Journal of Cardiology, 1999